On January 4, 2022, Judge Andrews from the United States District Court for the District of Delaware denied Sarepta Therapeutics,
Continue Reading Delaware Judge Denies Sarepta Protection Under Hatch-Waxman “Safe Harbor”
mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market.
Continue Reading mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
Laying Down the [Trademark] Law – The USPTO Signals Stricter Enforcement to Come
On June 8, 2021, the USPTO issued an Order to Show Cause to Shenzhen Huanyee Intellectual Property Co., Ltd. (“the
Continue Reading Laying Down the [Trademark] Law – The USPTO Signals Stricter Enforcement to Come
Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students
Introduction
Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each
Continue Reading Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students
Alphabet Dives Further Into AI-Driven Drug Discovery
Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to
Continue Reading Alphabet Dives Further Into AI-Driven Drug Discovery
Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems
Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in
Continue Reading Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems
Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million
On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million
Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy
On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy
Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow
Following the successful development (and financial success) of its mRNA vaccine, biotech company Moderna is now looking to expand into
Continue Reading Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow
Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO